GB Sciences (GBLX)

    Company Overview:

    GB has become a fully integrated life-science company with cultivation, extraction, and grow in Las Vegas. They’re also planning to expand to California, Texas and Louisiana; the company has made tremendous progress in all 3 states particularly Louisiana and California.

    Last year GB won a competitive bid to partner with LSU’s AgCenter. Together, they will grow and develop cannabis for patients with specific medical ailments including cancer, HIV, epilepsy and spasticity.

    The company has also executed an MOU for Los Coyotes Indian Reservation in California, which comes with all a 40k acre location and all requisite cultivation, production, and distribution licenses.

    GB has also pioneered tissue-culture propagation techniques to reduce genetic drift, which means they can consistently produce medical-grade cannabis for recreational or medical purposes. They’ve also refined the extraction process so they can maximize the quantity and quality of the active ingredients from each plant.

    GB is developing it’s own science. The company is working on cannabis based biopharmaceutical compounds for chronic pain and heart therapies,chronic arthritis, Crohn’s disease, inflammatory bowel disease and asthma. Early data is very good and they have several pending patents.

    Sylva's Take:

    We think GBLX could become the next GW Pharma, which is why we like it. The company has a solid management team including some very bright scientists that forging new ground in tissue propagation and medical therapies.

    GB also also has a fast-growing cannabis cultivation, production, and sale business which will provide cash flow to support the more ambitions pharmaceutical business. This company is hands down our favorite in the small-cap cannabis space.